GSK has found another potential way to treat cardiometabolic disease with a modality close to the pharma’s heart—oligonucleotides. The British drugmaker is paying $55 million upfront to China’s ...

The buyout, which includes up to $2.15 billion in milestones, will give Bayer control of an eye disease implant that Perfuse ...

Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than ...

In the last three years, CellCentric CEO Will West has been on a journey that has transformed how he thinks about the future ...

A phase 2 trial of Avalo Therapeutics’ hidradenitis suppurativa (HS) candidate hit its primary endpoint, emboldening the ...

Novo Nordisk’s CEO has insisted that plans to launch the GLP-1/amylin combo treatment CagriSema remain on track, despite the ...

Johnson & Johnson MedTech is touting positive results from the first clinical study of its Ottava soft-tissue surgical robot, showing the system can safely perform gastric bypass surgery. J&J said ...

Gilead will lay off 108 workers from Arcellx’s site at 800 Bridge Parkway in Redwood City, CA, according to a Worker ...

Madrigal Pharmaceuticals' hunger for fresh metabolic dysfunction-associated steatohepatitis (MASH) drugs shows no sign of ...

Pfizer’s $2.3 billion bet on Trillium Therapeutics doesn’t look like it will ever pay out, with the Big Pharma abandoning the ...

In March, Viridian posted a phase 3 win for elegrobart in active TED, defined as patients who developed symptoms within 15 ...

After pausing a trial for a Moderna-partnered cystic fibrosis candidate due to subpar tolerability, Vertex Pharmaceuticals ...